Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895397 | 0.91 | — | — | |
| SCHEMBL10831008 | 0.74 | — | — | |
| SCHEMBL10751050 | 0.74 | — | — | |
| SCHEMBL10456443 | 0.72 | — | — | |
| SCHEMBL258395 | 0.69 | — | — | |
| SCHEMBL11416603 | 0.69 | — | — | |
| SCHEMBL10745513 | 0.67 | TDP1 (0.40) | TDP1 | |
| SCHEMBL3120166 | 0.67 | HRH3 (0.47) | — | |
| SCHEMBL9860827 | 0.67 | TDP1 (0.32) | TDP1 | |
| SCHEMBL9713560 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170067045-A1 | PEPTIDE LIBRARIES | BICYCLE THERAPEUTICS LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| US-9518081-B2 | Peptide libraries | BICYCLE THERAPEUTICS LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| CN-102850544-B | Polymeric salts and poly-NHC-metal complexes | INST OF BIOENGINEERING AND NANOTECHNOLOGY | 2015-04-15 | — | — | CN | disclosed |
| EP-2464727-B1 | PEPTIDE LIBRARIES | BICYCLE THERAPEUTICS LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| US-20120172235-A1 | PEPTIDE LIBRARIES | MEDICAL RESEARCH COUNCIL (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2464727-A2 | PEPTIDE LIBRARIES | Medical Research Council (GB) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011018227-A2 | PEPTIDE LIBRARIES | MEDICAL RESEARCH COUNCIL (GB) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172235-A1 | PEPTIDE LIBRARIES | MICA, SPPL2B, PTMS | TDP1 2601/4885 |
| US-20170067045-A1 | PEPTIDE LIBRARIES | MICA, SPPL2B, PTMS | TDP1 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.